Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.

Jiayu Li, Shuhan Ma, Hongdi Pei, Jici Jiang, Quan Zou, Zhibin Lv

Abstract readReview

In one paragraph

Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiayu LiStudent Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.

Shuhan MaStudent Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.

Hongdi PeiStudent Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.

Jici JiangStudent Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.

Quan ZouInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 610054, China.

Zhibin LvStudent Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell proliferation regulators (Tcprs), which are positive regulators that promote T cell function, have made great contributions to the development of therapies to improve T cell function. CAR (chimeric antigen receptor) -T cell therapy, a type of adoptive cell transfer therapy that targets tumor cells and enhances immune lethality, has led to significant progress in the treatment of hematologic tumors. However, the applications of CAR-T in solid tumor treatment remain limited. Therefore, in this review, we focus on the development of Tcprs for solid tumor therapy and prognostic prediction. We summarize potential strategies for targeting different Tcprs to enhance T cell proliferation and activation and inhibition of cancer progression, thereby improving the antitumor activity and persistence of CAR-T. In summary, we propose means of enhancing CAR-T cells by expressing different Tcprs, which may lead to the development of a new generation of cell therapies.

Indexed as

Cancer prognosis predictionCAR-TImmunocyte therapySolid tumorT cell proliferation and activationT cell proliferation regulators

Identifiers

PMID37954355

DOI10.1016/j.heliyon.2023.e21329

PMCPMC10637962

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.